Evidence map›Paper›PMID 27672331›Full record

ArticleOncoTargets and therapy2016

Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients.

Ali Suner, Hakan Buyukhatipoglu, Gokmen Aktas, Tulay Kus, Mustafa Ulasli, Serdar Oztuzcu, Mehmet Emin Kalender, Alper Sevinc, Seval Kul, Celaletdin Camci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ali SunerDivision of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Hakan BuyukhatipogluDivision of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Gokmen AktasDivision of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Tulay KusDivision of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Mustafa UlasliDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
Serdar OztuzcuDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
Mehmet Emin KalenderDivision of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Alper SevincDivision of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.
Seval KulDepartment of Biostatistics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
Celaletdin CamciDivision of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study is to clarify the relationship between recurrence risk of breast cancer and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms. PATIENTS AND

methodsBreast cancer patients who had undergone surgery in Gaziantep University Oncology Hospital between June 2005 and June 2012 were followed-up and retrospectively enrolled in this study. Blood samples were collected from all patients to assess MTHFR C677T polymorphisms. Stage according to tumor-node-metastasis system, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 status, grade of disease, menopausal status, and administered chemotherapy or hormonal therapy were recorded. Effects of these parameters on recurrence risk were evaluated using univariate analysis and multivariate binary logistic regression model.

resultsAssociation of MTHFR C677T polymorphisms with recurrence risk was evaluated in 298 patients whose median age was 47 years (range: 21-79 years). In all patients, age (odds ratio [OR] =0.953, P=0.005) and N3 lymph node status (OR =6.293, P=0.001) were found to affect the recurrence risk. While MTHFR homozygote genotype did not have an effect on recurrence risk in all patients, increased risk was observed in lymph node-positive subgroup (OR =4.271; 95% CI 1.515-12.023; P=0.006). Adjusting for age, tumor size (T), and node status (N), MTHFR homozygote genotype had more statistically significant risk for recurrence (OR =3.255; 95% CI 1.047-10.125; P=0.041).

conclusionMTHFR TT genotype was found to be associated with increased recurrence risk in patients with lymph node-positive breast cancer.

Indexed as

breast cancermethylenetetrahydrofolate reductaseMTHFRrecurrence riskrs9651118 polymorphism

Identifiers

PMID27672331
PMCPMC5024764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.